

Catalog# BP- 50571

## Drozitumab Biosimilar (TRAIL Monoclonal Antibody)

Droazitumab Biosimilar uses the same protein sequences as the therapeutic antibody drozitumab.

Droazitumab is a human monoclonal antibody in development for the treatment of cancers. It targets Tumour Necrosis Factor Related Apoptosis-inducing Ligand (TRAIL), whose receptors are found on the surface of many types of malignant cells.

Although drozitumab was studied in phase II trials for treating chondrosarcoma, colorectal cancer, non-Hodgkin lymphoma, and non-small cell lung cancer, development has been halted due to lack of clinical response.

Product Details	
CAS No.	912628-39-8
Species Reactivity	Human
Source	Mammalian cells
Isotype	Human IgG1 kappa
Class	Monoclonal
Type	Antibody
Clone	Droazitumab Biosimilar
Conjugate	Unconjugated
Immunogen	Death receptor DR5 and induces apoptosis
Purity	>95%
Molecular Weight	143.06 kDa
Protein Concentration	1 mg/ml
Formulation	0.2 µM filtered solution, pH 6.0
Storage conditions	4°C for short time, -20°C or -80°C for long time.